Combinostics, a Tampere, Finland-based health tech company, closed a €3.9M Series A funding round.
The round was jointly-led by Industrifonden and NordicNinja VC.
The company inrends to use the funds to scale its platform for early-stage Alzheimer’s diagnosis to the US and Asia.
Founded in 2014 and led by CEO Lennart Thurfjell, Combinostics aims to support healthcare professionals in the diagnosis and treatment of neurodegenerative diseases with the overall goal to improve patient quality of life in later years. Its cNeuro platform combines imaging data with clinical data and provides an holistic view of patient data that highlights important relationships early on and supports early diagnosis. Users include radiology and neurology departments in the EU, US, Japan, and South Korea.